FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387166802> ?p ?o ?g. }

• W4387166802 abstract "Abstract Background The effect of the combination of an anti-angiogenic agent with a poly (ADP-ribose) polymerase (PARP) inhibitor in cancer treatment is unclear. We assessed the oral combination of fuzuloparib, a PARP inhibitor, and apatinib, a VEGFR2 inhibitor for treating advanced ovarian cancer (OC) or triple-negative breast cancer (TNBC). Methods This dose-escalation and pharmacokinetics-expansion phase 1 trial was conducted in China. We used a standard 3 + 3 dose-escalation design, with 7 dose levels tested. Patients received fuzuloparib orally twice daily, and apatinib orally once daily. The study objectives were to determine the safety profile, recommended phase 2 dose (RP2D), pharmacokinetics, preliminary efficacy, and efficacy in relation to germline BRCA mutation (g BRCA mut ). Results Fifty-two pre-treated patients were enrolled (30 OC/22 TNBC). 5 (9.6%) patients had complete response, 14 (26.9%) had partial response, and 15 (28.8%) had stable disease. Objective response rate (ORR) and disease control rate were 36.5% (95% CI 23.6–51.0) and 65.4% (95% CI 50.9–78.0), respectively. At the highest dose level of fuzuloparib 100 mg plus apatinib 500 mg, the ORR was 50.0% (4/8; 95% CI 15.7–84.3); this dose was determined to be the RP2D. Patients with g BRCA mut had higher ORR and longer median progression-free survival (PFS) than those with g BRCA wt , both in OC (ORR, 62.5% [5/8] vs 40.9% [9/22]; PFS, 9.4 vs 6.7 months) and TNBC (ORR, 66.7% [2/3] vs 15.8% [3/19]; PFS, 5.6 vs 2.8 months). Two dose-limiting toxicities occurred: grade 4 febrile neutropenia (fuzuloparib 100 mg plus apatinib 250 mg) and thrombocytopenia (fuzuloparib 100 mg plus apatinib 375 mg). Maximum tolerated dose was not reached. The most common treatment-related grade ≥ 3 toxicities in all patients were hypertension (19.2%), anaemia (13.5%), and decreased platelet count (5.8%). Exposure of apatinib increased proportionally with increasing dose ranging from 250 to 500 mg, when combined with fuzuloparib 100 mg. Conclusions Fuzuloparib plus apatinib had acceptable safety in patients with advanced OC or TNBC. Fuzuloparib 100 mg bid plus apatinib 500 mg qd was established as the RP2D. With the promising clinical activity observed, this combination is warranted to be further explored as a potential alternative to chemotherapy. Trial registration ClinicalTrials.gov, NCT03075462 (Mar. 9, 2017)." @default.
• W4387166802 created "2023-09-30" @default.
• W4387166802 creator A5003088149 @default.
• W4387166802 creator A5005995308 @default.
• W4387166802 creator A5009953160 @default.
• W4387166802 creator A5011307607 @default.
• W4387166802 creator A5019876833 @default.
• W4387166802 creator A5022765898 @default.
• W4387166802 creator A5028616197 @default.
• W4387166802 creator A5036990231 @default.
• W4387166802 creator A5041513544 @default.
• W4387166802 creator A5041966023 @default.
• W4387166802 creator A5045553246 @default.
• W4387166802 creator A5049280385 @default.
• W4387166802 creator A5060589194 @default.
• W4387166802 creator A5070830488 @default.
• W4387166802 creator A5075065460 @default.
• W4387166802 creator A5085788510 @default.
• W4387166802 creator A5088829354 @default.
• W4387166802 creator A5090765880 @default.
• W4387166802 date "2023-09-29" @default.
• W4387166802 modified "2023-10-11" @default.
• W4387166802 title "A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis" @default.
• W4387166802 cites W1973268287 @default.
• W4387166802 cites W2005526381 @default.
• W4387166802 cites W2044702943 @default.
• W4387166802 cites W2096283457 @default.
• W4387166802 cites W2113467627 @default.
• W4387166802 cites W2123696077 @default.
• W4387166802 cites W2146373785 @default.
• W4387166802 cites W2151509048 @default.
• W4387166802 cites W2158742893 @default.
• W4387166802 cites W2173456459 @default.
• W4387166802 cites W2179105349 @default.
• W4387166802 cites W2276228008 @default.
• W4387166802 cites W2560367415 @default.
• W4387166802 cites W2621271973 @default.
• W4387166802 cites W2754327139 @default.
• W4387166802 cites W2789481433 @default.
• W4387166802 cites W2802074519 @default.
• W4387166802 cites W2886354380 @default.
• W4387166802 cites W2913333080 @default.
• W4387166802 cites W2913578326 @default.
• W4387166802 cites W2970135300 @default.
• W4387166802 cites W2976139792 @default.
• W4387166802 cites W3042212874 @default.
• W4387166802 cites W3113054844 @default.
• W4387166802 cites W3127737940 @default.
• W4387166802 cites W3130309722 @default.
• W4387166802 cites W3156985612 @default.
• W4387166802 cites W3161525867 @default.
• W4387166802 cites W3185139931 @default.
• W4387166802 cites W3198055123 @default.
• W4387166802 cites W3203356683 @default.
• W4387166802 cites W3213834237 @default.
• W4387166802 cites W4206535779 @default.
• W4387166802 cites W4223475582 @default.
• W4387166802 cites W4226282713 @default.
• W4387166802 cites W4289525182 @default.
• W4387166802 doi "https://doi.org/10.1186/s12916-023-03046-8" @default.
• W4387166802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37775744" @default.
• W4387166802 hasPublicationYear "2023" @default.
• W4387166802 type Work @default.
• W4387166802 citedByCount "0" @default.
• W4387166802 crossrefType "journal-article" @default.
• W4387166802 hasAuthorship W4387166802A5003088149 @default.
• W4387166802 hasAuthorship W4387166802A5005995308 @default.
• W4387166802 hasAuthorship W4387166802A5009953160 @default.
• W4387166802 hasAuthorship W4387166802A5011307607 @default.
• W4387166802 hasAuthorship W4387166802A5019876833 @default.
• W4387166802 hasAuthorship W4387166802A5022765898 @default.
• W4387166802 hasAuthorship W4387166802A5028616197 @default.
• W4387166802 hasAuthorship W4387166802A5036990231 @default.
• W4387166802 hasAuthorship W4387166802A5041513544 @default.
• W4387166802 hasAuthorship W4387166802A5041966023 @default.
• W4387166802 hasAuthorship W4387166802A5045553246 @default.
• W4387166802 hasAuthorship W4387166802A5049280385 @default.
• W4387166802 hasAuthorship W4387166802A5060589194 @default.
• W4387166802 hasAuthorship W4387166802A5070830488 @default.
• W4387166802 hasAuthorship W4387166802A5075065460 @default.
• W4387166802 hasAuthorship W4387166802A5085788510 @default.
• W4387166802 hasAuthorship W4387166802A5088829354 @default.
• W4387166802 hasAuthorship W4387166802A5090765880 @default.
• W4387166802 hasBestOaLocation W43871668021 @default.
• W4387166802 hasConcept C104317684 @default.
• W4387166802 hasConcept C112705442 @default.
• W4387166802 hasConcept C121608353 @default.
• W4387166802 hasConcept C126322002 @default.
• W4387166802 hasConcept C143998085 @default.
• W4387166802 hasConcept C182979987 @default.
• W4387166802 hasConcept C185592680 @default.
• W4387166802 hasConcept C2777088508 @default.
• W4387166802 hasConcept C2779138821 @default.
• W4387166802 hasConcept C2780110267 @default.
• W4387166802 hasConcept C2780194787 @default.
• W4387166802 hasConcept C2780427987 @default.
• W4387166802 hasConcept C2780668389 @default.
• W4387166802 hasConcept C530470458 @default.
• W4387166802 hasConcept C55493867 @default.
• W4387166802 hasConcept C71924100 @default.

• next